What is Wedbush’s Forecast for Ardelyx Q2 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Wedbush decreased their Q2 2025 earnings estimates for shares of Ardelyx in a report issued on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($0.09) per share for the quarter, down from their prior estimate of ($0.08). The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.32) EPS.

A number of other analysts also recently weighed in on the stock. HC Wainwright started coverage on shares of Ardelyx in a research report on Wednesday, June 18th. They issued a “buy” rating and a $10.00 price target on the stock. Citigroup lowered their target price on shares of Ardelyx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Wall Street Zen lowered shares of Ardelyx from a “hold” rating to a “sell” rating in a report on Monday, May 5th. Finally, Raymond James Financial lowered shares of Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 price target for the company. in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.89.

Ardelyx Trading Down 1.7%

NASDAQ:ARDX opened at $4.52 on Thursday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -20.55 and a beta of 0.60. Ardelyx has a 1-year low of $3.21 and a 1-year high of $7.18. The business’s 50-day moving average price is $3.92 and its two-hundred day moving average price is $4.71. The company has a current ratio of 4.12, a quick ratio of 3.81 and a debt-to-equity ratio of 1.04.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Ardelyx had a negative return on equity of 34.45% and a negative net margin of 14.86%. The company had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 61.1% on a year-over-year basis.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, Director David M. Mott purchased 200,000 shares of the stock in a transaction on Monday, June 16th. The shares were purchased at an average cost of $3.63 per share, for a total transaction of $726,000.00. Following the purchase, the director owned 2,896,871 shares of the company’s stock, valued at approximately $10,515,641.73. This represents a 7.42% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 46,817 shares of Ardelyx stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $191,013.36. Following the completion of the sale, the chief executive officer directly owned 1,547,937 shares in the company, valued at approximately $6,315,582.96. This represents a 2.94% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 881,377 shares of company stock valued at $3,402,411 and sold 125,143 shares valued at $517,667. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ARDX. Janus Henderson Group PLC grew its stake in shares of Ardelyx by 13.3% in the fourth quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company’s stock valued at $123,587,000 after buying an additional 2,858,061 shares in the last quarter. Vanguard Group Inc. raised its stake in Ardelyx by 4.4% in the first quarter. Vanguard Group Inc. now owns 14,997,234 shares of the biopharmaceutical company’s stock valued at $73,636,000 after buying an additional 634,575 shares during the period. Millennium Management LLC lifted its position in shares of Ardelyx by 118.2% in the first quarter. Millennium Management LLC now owns 6,465,262 shares of the biopharmaceutical company’s stock valued at $31,744,000 after buying an additional 3,501,782 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Ardelyx by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,730 shares of the biopharmaceutical company’s stock worth $27,941,000 after acquiring an additional 21,988 shares during the period. Finally, Nuveen LLC acquired a new position in shares of Ardelyx during the 1st quarter worth approximately $16,735,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.